SA517381991B1 - أجسام مضادة لترانس ثيرتين - Google Patents
أجسام مضادة لترانس ثيرتينInfo
- Publication number
- SA517381991B1 SA517381991B1 SA517381991A SA517381991A SA517381991B1 SA 517381991 B1 SA517381991 B1 SA 517381991B1 SA 517381991 A SA517381991 A SA 517381991A SA 517381991 A SA517381991 A SA 517381991A SA 517381991 B1 SA517381991 B1 SA 517381991B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- ttr
- antibodies
- transthyretin
- accumulation
- amyloidosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
أجسام مضادة لترانس ثيرتين Anti-Transthyretin Antibodies الملخـــص يتعلق الاختراع الحالي بتوفير أجسام مضادة antibodies ترتبط بشكل خاص بترانس ثيرتين transthyretin (TTR). يمكن استخدام الأجسام المضادة antibodies لعلاج أو تفعيل الوقاية effecting prophylaxis من الأمراض diseases أو الاضطرابات disorders المصحوبة بتراكم TTR TTR accumulation أو تراكم رواسب TTR accumulation of TTR deposits (على سبيل المثال، الداء النشواني amyloidosis الناتج عن TTR). يمكن أيضًا استخدام الأجسام المضادة antibodies لتشخيص الداء النشواني amyloidosis الناتج عن TTR وتثبيط أو خفض تَكَدُّس TTR reducing aggregation of TTR، من بين تطبيقات أخرى. شكل 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562109001P | 2015-01-28 | 2015-01-28 | |
US201562266557P | 2015-12-11 | 2015-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SA517381991B1 true SA517381991B1 (ar) | 2021-12-13 |
Family
ID=55361912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA517381991A SA517381991B1 (ar) | 2015-01-28 | 2017-07-26 | أجسام مضادة لترانس ثيرتين |
Country Status (20)
Country | Link |
---|---|
US (1) | US20160257736A1 (ar) |
EP (1) | EP3250594B1 (ar) |
JP (2) | JP6875280B2 (ar) |
KR (1) | KR102619359B1 (ar) |
CN (1) | CN107428822B (ar) |
AU (1) | AU2016210887B2 (ar) |
BR (1) | BR112017016324A2 (ar) |
CA (1) | CA2974911A1 (ar) |
CO (1) | CO2017008469A2 (ar) |
CU (1) | CU24532B1 (ar) |
EA (1) | EA036048B1 (ar) |
ES (1) | ES2905311T3 (ar) |
MX (1) | MX2017009804A (ar) |
MY (1) | MY193674A (ar) |
PE (1) | PE20180200A1 (ar) |
SA (1) | SA517381991B1 (ar) |
SG (1) | SG11201706125QA (ar) |
TW (2) | TWI718121B (ar) |
WO (1) | WO2016120809A1 (ar) |
ZA (1) | ZA201705662B (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7016470B2 (ja) * | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
EP3478716A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7292569B2 (ja) * | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー/エス | トランスサイレチンを検出する方法 |
MX2020003041A (es) * | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
MA51223A (fr) | 2017-11-29 | 2020-10-07 | Prothena Biosciences Ltd | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
EP2808020A1 (en) | 2006-04-21 | 2014-12-03 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-Amyloid Pet Imaging Agents |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
PT2126093E (pt) | 2007-03-02 | 2012-12-03 | Boehringer Ingelheim Pharma | Melhoramento da produção de proteínas |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
WO2010030203A1 (en) * | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
EP2953970A4 (en) * | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | TRANSTYRETIN ANTIBODIES AND USES THEREOF |
TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2016
- 2016-01-27 TW TW105102534A patent/TWI718121B/zh active
- 2016-01-27 TW TW110100084A patent/TWI781507B/zh active
- 2016-01-28 CN CN201680015800.8A patent/CN107428822B/zh active Active
- 2016-01-28 ES ES16704940T patent/ES2905311T3/es active Active
- 2016-01-28 MY MYPI2017702749A patent/MY193674A/en unknown
- 2016-01-28 MX MX2017009804A patent/MX2017009804A/es unknown
- 2016-01-28 EA EA201791711A patent/EA036048B1/ru unknown
- 2016-01-28 CA CA2974911A patent/CA2974911A1/en active Pending
- 2016-01-28 US US15/009,666 patent/US20160257736A1/en not_active Abandoned
- 2016-01-28 AU AU2016210887A patent/AU2016210887B2/en active Active
- 2016-01-28 CU CU2017000096A patent/CU24532B1/es unknown
- 2016-01-28 JP JP2017540249A patent/JP6875280B2/ja active Active
- 2016-01-28 SG SG11201706125QA patent/SG11201706125QA/en unknown
- 2016-01-28 PE PE2017001286A patent/PE20180200A1/es unknown
- 2016-01-28 WO PCT/IB2016/050414 patent/WO2016120809A1/en active Application Filing
- 2016-01-28 EP EP16704940.2A patent/EP3250594B1/en active Active
- 2016-01-28 KR KR1020177023748A patent/KR102619359B1/ko active IP Right Grant
- 2016-01-28 BR BR112017016324A patent/BR112017016324A2/pt active Search and Examination
-
2017
- 2017-07-26 SA SA517381991A patent/SA517381991B1/ar unknown
- 2017-08-21 ZA ZA2017/05662A patent/ZA201705662B/en unknown
- 2017-08-22 CO CONC2017/0008469A patent/CO2017008469A2/es unknown
-
2021
- 2021-04-22 JP JP2021072547A patent/JP7219928B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7219928B2 (ja) | 2023-02-09 |
AU2016210887B2 (en) | 2021-11-04 |
KR102619359B1 (ko) | 2024-01-02 |
WO2016120809A1 (en) | 2016-08-04 |
BR112017016324A2 (pt) | 2018-03-27 |
TW202118782A (zh) | 2021-05-16 |
CO2017008469A2 (es) | 2018-01-16 |
TWI718121B (zh) | 2021-02-11 |
MY193674A (en) | 2022-10-24 |
AU2016210887A1 (en) | 2017-08-10 |
CU24532B1 (es) | 2021-07-02 |
EA201791711A1 (ru) | 2017-11-30 |
EP3250594B1 (en) | 2021-11-17 |
PE20180200A1 (es) | 2018-01-31 |
ZA201705662B (en) | 2018-08-29 |
CN107428822A (zh) | 2017-12-01 |
ES2905311T3 (es) | 2022-04-07 |
US20160257736A1 (en) | 2016-09-08 |
JP2021129562A (ja) | 2021-09-09 |
MX2017009804A (es) | 2018-08-15 |
EA036048B1 (ru) | 2020-09-18 |
CN107428822B (zh) | 2021-11-23 |
KR20170120607A (ko) | 2017-10-31 |
JP6875280B2 (ja) | 2021-05-26 |
TW201636372A (zh) | 2016-10-16 |
CA2974911A1 (en) | 2016-08-04 |
EP3250594A1 (en) | 2017-12-06 |
CU20170096A7 (es) | 2018-03-13 |
JP2018509889A (ja) | 2018-04-12 |
SG11201706125QA (en) | 2017-08-30 |
TWI781507B (zh) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501318B1 (en) | Anti-transthyretin antibodies | |
SA517381991B1 (ar) | أجسام مضادة لترانس ثيرتين | |
SA517381981B1 (ar) | أجسام مضادة لترانس ثيرتين | |
WO2018007924A3 (en) | Anti-transthyretin antibodies | |
MX2020003041A (es) | Anticuerpos anti-transtiretina. | |
WO2018007923A3 (en) | Anti-transthyretin antibodies | |
WO2018007922A3 (en) | Anti-transthyretin antibodies | |
MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
PH12020550141A1 (en) | Antibody molecules to cd138 and uses thereof | |
CL2020002468A1 (es) | Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018) | |
MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
MY193688A (en) | Anti-transthyretin antibodies | |
EA202090891A1 (ru) | Молекулы антител против cd138 и их применение | |
EA202090898A1 (ru) | Антитранстиретиновые антитела | |
PH12020552202A1 (en) | Antibody molecules to complement component 5 and uses thereof | |
NZ730759A (en) | 1,2-benzothiazole compounds for the treatment of kidney disorders |